drugset / Trial / NCT06179069
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
Timeline
- Start
- 2024-01-23
- Primary completion
- 2027-05-30
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | ZL-1310 | Other / unclassified | — | — |